Last reviewed · How we verify

Nitrogen-oxygen breathing mixture

University of Plymouth · Phase 3 active Small molecule Under review

Nitrogen-oxygen breathing mixture is a Small molecule drug developed by University of Plymouth. It is currently in Phase 3 development for Decompression sickness (the bends), Nitrogen narcosis mitigation in deep diving.

A nitrogen-oxygen breathing mixture modulates inspired gas composition to alter oxygen and nitrogen partial pressures in the blood and tissues.

Nitrogen-oxygen breathing mixture, also known as MEOPA, is an equimolar mixture of nitrogen and oxygen used in clinical settings. Nitrogen and oxygen are essential small molecules for cellular homeostasis.

Likelihood of approval
58.3% vs 58.3% industry baseline
If approved by FDA: likely 2028–2030
Steps remaining: NDA/BLA submission
Confidence: High
Why this estimate
  • Baseline phase 3 → approval rate +58.3pp
    Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Predicted approval windows by jurisdiction (conditional on FDA approval)
Regulator Country Likely year Lag vs FDA
FDA US 2028–2030
EMA EU 2029–2031 +0.7 yr
MHRA GB 2029–2031 +0.7 yr
Health Canada CA 2029–2032 +0.9 yr
TGA AU 2029–2032 +1.2 yr
PMDA JP 2029–2032 +1.5 yr
NMPA CN 2030–2033 +2.3 yr
MFDS KR 2029–2032 +1.4 yr
CDSCO IN 2029–2033 +1.8 yr
ANVISA BR 2030–2033 +2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic nameNitrogen-oxygen breathing mixture
SponsorUniversity of Plymouth
ModalitySmall molecule
Therapeutic areaRespiratory/Hyperbaric Medicine
PhasePhase 3

Mechanism of action

By adjusting the ratio of nitrogen to oxygen in inspired air, this therapeutic gas mixture changes the physiological effects of inert gas narcosis and oxygen toxicity, potentially improving oxygen delivery, reducing decompression stress, or modulating inflammatory responses. The specific mechanism depends on the exact nitrogen-oxygen ratio used and the intended therapeutic target.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Nitrogen-oxygen breathing mixture

What is Nitrogen-oxygen breathing mixture?

Nitrogen-oxygen breathing mixture is a Small molecule drug developed by University of Plymouth, indicated for Decompression sickness (the bends), Nitrogen narcosis mitigation in deep diving.

How does Nitrogen-oxygen breathing mixture work?

A nitrogen-oxygen breathing mixture modulates inspired gas composition to alter oxygen and nitrogen partial pressures in the blood and tissues.

What is Nitrogen-oxygen breathing mixture used for?

Nitrogen-oxygen breathing mixture is indicated for Decompression sickness (the bends), Nitrogen narcosis mitigation in deep diving.

Who makes Nitrogen-oxygen breathing mixture?

Nitrogen-oxygen breathing mixture is developed by University of Plymouth (see full University of Plymouth pipeline at /company/university-of-plymouth).

What development phase is Nitrogen-oxygen breathing mixture in?

Nitrogen-oxygen breathing mixture is in Phase 3.

What are the side effects of Nitrogen-oxygen breathing mixture?

Common side effects of Nitrogen-oxygen breathing mixture include Oxygen toxicity, Nitrogen narcosis, Hypoxia.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing